-+ 0.00%
-+ 0.00%
-+ 0.00%

Kazia Therapeutics Reports Regulatory Approval And Launch Of Clinical Trial Evaluating Combination Of Paxalisib And Immunotherapy In Patients With Advanced Breast Cancer

Benzinga·01/30/2025 12:32:15
Listen to the news

ABC-Pax is a multi-centre, open-label phase 1b study that will enroll 24 patients from top cancer centres in Queensland, Australia and patients will receive the combination therapy for up to 12 months.